Cardiorenal connection in chronic kidney disease

Sadayoshi Ito1

  • 1Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. ishisho@med.tohoku.ac.jp

Insights

Chronic kidney disease (CKD) significantly increases cardiovascular event risk, independent of traditional factors. Microalbuminuria, a CKD marker, is a key risk factor, potentially linked through the renin-angiotensin system (RAS).

Area of Science:

  • Nephrology
  • Cardiology
  • Public Health

Background:

  • Chronic kidney disease (CKD) is a growing public health concern, defined by reduced kidney function or damage.
  • CKD independently elevates cardiovascular event risk beyond established factors like hypertension and diabetes.
  • Microalbuminuria, a marker of kidney damage, is a significant cardiovascular risk factor in various populations.

Purpose of the Study:

  • To investigate the mechanisms linking CKD to cardiovascular events.
  • To explore the role of microalbuminuria and salt sensitivity in this association.
  • To discuss the 'strain vessel hypothesis' and the impact of underlying diseases and RAS inhibition.

Main Methods:

  • Review of epidemiological studies and current research on CKD and cardiovascular risk.
  • Analysis of potential mechanisms including the renin-angiotensin system (RAS), oxidative stress, and inflammation.
  • Discussion of hemodynamic factors and the 'strain vessel hypothesis' for cerebrocardiorenal connections.

Main Results:

  • CKD is an independent risk factor for cardiovascular events.
  • Microalbuminuria is a significant predictor of cardiovascular disease, even in normotensive individuals.
  • Salt sensitivity is closely associated with microalbuminuria and cardiovascular risk.

Conclusions:

  • CKD poses a substantial threat to cardiovascular health through various interconnected mechanisms.
  • Understanding these links, including the 'strain vessel hypothesis', is crucial for patient management.
  • RAS inhibition may play a role in managing cardiovascular risks in CKD patients.

Related Concept Videos

Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...